Robotic central pancreatectomy may be used in selected patients in experienced centers. This protocol presents all steps and the feasibility of a robotic central pancreatectomy with Roux-en-Y pancreaticojejunostomy in a 16-year-old adolescent patient.
Central pancreatectomy is a parenchyma-sparing alternative to distal pancreatectomy in patients with a benign or low-grade malignant tumor in the body of the pancreas. The aim of central pancreatectomy is to prevent postoperative life-long endocrine and exocrine insufficiency. The downside of central pancreatectomy is the high rate of postoperative pancreatic fistula, which is the main reason that many surgeons do not routinely use central pancreatectomy in eligible patients. Most studies report open or laparoscopic central pancreatectomy with a pancreatico-gastrostomy anastomosis in adults. This is the first description of a standardized approach to robotic central pancreatectomy with Roux-en-Y pancreaticojejunostomy reconstruction in an adolescent (16-year-old boy) with a pseudopapillary tumor in the body of the pancreas. The operation time was 248 min with 20 mL of blood loss. The postoperative course was uneventful except for the short-term medical treatment for a grade B pancreatic fistula. Robotic central pancreatectomy can be safely applied in selected patients in experienced centers.
Central pancreatectomy has been described as a parenchyma-sparing alternative surgical procedure to distal pancreatectomy for benign or low-grade malignant lesions located in the body of the pancreas1,2. Central pancreatectomy will prevent life-long pancreatic endocrine and exocrine dysfunction in most patients. Still, most surgeons chose to perform a distal pancreatectomy over a central pancreatectomy because of the increased risk of postoperative morbidity, mainly due to postoperative pancreatic fistula (POPF) after central pancreatectomy3,4,5. In fact, central pancreatectomy combines the POPF risk of a distal pancreatectomy and a pancreato-enteric anastomosis.
Most studies on central pancreatectomy advise to perform a pancreatico-gastrostomy anastomosis because of the presumed lower risk of POPF6,7. However, current randomized trials are inconclusive regarding the risk for POPF incidence for pancreatico-gastrostomy and pancreaticojejunostomy8,9,10. Furthermore, pancreatico-gastrostomy has been suggested to impair long-term pancreatic exocrine function due to gastric mucosal overgrowth11. In addition, the minority of surgeons are experienced with pancreatico-gastrostomy in daily clinical practice, which will also reduce enthusiasm for this solution.
Robotic pancreatoduodenectomy, supported by the work of the Pittsburgh University Medical Center team and large-scale training programs such as the Dutch LAELAPS-3 and the European LEARNBOT programs, has now become an accepted approach in selected patients in many centers across the world12,13,14. For surgeons experienced with robotic pancreatoduodenectomy, including the highly standardized robotic pancreatico-jejunal anastomosis, a robotic central pancreatectomy is an attractive alternative to open or laparoscopic central pancreatectomy or laparoscopic distal pancreatectomy.
In this article, we describe a case of a 16-year-old adolescent patient with a pancreatic lesion suspected for solid pseudopapillary tumor who underwent robotic central pancreatectomy with Roux-en-Y pancreaticojejunostomy reconstruction. Our aim is to demonstrate the technical approach and clinical safety of robotic-assisted central pancreatectomy and its surgical outcomes when performed in high-volume centers by experienced surgeons.
The present protocol follows the ethics guidelines of the Amsterdam UMC. Informed consent was obtained from the patient for this article and the video.
1. Preoperative management
2. Operative setting
3. Pancreatic identification and mobilization
4. Pancreatic transection
5. Window in the mesocolon
6. Creating Roux-limb
7. Positioning Roux-limb
8. Jejuno-jejunostomy
9. Pancreaticojejunostomy
10. Drain placement
11. Postoperative management
Representative results are shown in Table 1. The operation time was 248 min with a measured blood loss of 20 mL. The postoperative course was uncomplicated. Because of initially high drain amylase the patient received octreotide and antibiotics for 3 days. This treatment was stopped when drain amylase levels normalized on postoperative day 7, when the drain was also removed. Because of this medical treatment, this was graded as a grade B POPF17. A normal diet could be restarted after 4 days. The patient was discharged in good condition on postoperative day 8. The patient did not develop diabetes or pancreatic exocrine insufficiency during the follow-up.
Pathology assessment revealed a 2.2 cm solid pseudopapillary tumor (Figure 4) and thus confirming the preoperative diagnosis. Microscopically, an R0 resection was confirmed. One lymph node was excised, in which localization of tumor tissue was not found.
Figure 1: Trocar placement. Red: 8 mm robotic trocars, blue: 12 mm laparoscopic trocars, yellow: 5 mm trocar for stomach/liver retractor. Please click here to view a larger version of this figure.
Figure 2: Schematic trocar placement. Please click here to view a larger version of this figure.
Figure 3: Set up and installation of the robot during surgery. Please click here to view a larger version of this figure.
Figure 4: Macroscopic specimen. Please click here to view a larger version of this figure.
Variable | Outcome |
Intraoperative | |
Operative time, minutes | 248 |
Intraoperative blood loss, mL | 20 |
Postoperative | |
Postoperative pancreatic fistula (POPF) | Grade B |
Clavien-Dindo complication grade | 2 |
Drain removal, postoperative day | 7 |
Postoperative hospital stay, days | 8 |
Pathological diagnosis | Radically (R0) resected solid pseudopapillary tumor (i.e. Frantz tumor), 2.2 cm |
Table 1: Representative results of the surgery.
This report demonstrates that robotic central pancreatectomy with Roux-en-Y pancreaticojejunostomy is feasible in selected patients and in experienced hands. In our experience, the robotic approach has benefits compared to the laparoscopic approach, especially when an anastomosis has to be made, due to its enhanced technical capabilities such as surgeon controlled high definition three-dimensional vision, facilitated and magnified instrument movement, and inherently to this improved suturing control due to its wristed instruments18,19. In particular, our report demonstrated that the standard pancreatico-jejunal anastomosis from robotic pancreatoduodenectomy could be used.
A recent multicenter NSQIP analysis reported a reduced risk of POPF after robotic as compared to open pancreatoduodenectomy20. Therefore, the question arises whether robotic central pancreatectomy could reduce the risk of POPF when compared to open central pancreatectomy.
Nonetheless, patient characteristics and the risk of a POPF should be taken into account when determining whether to perform a central pancreatectomy. The rate of POPF after central pancreatectomy will remain higher than after distal pancreatectomy given the POPF rate of pancreaticojejunostomy. Therefore, central pancreatectomy should be reserved for patients who are at low risk of POPF or other complications. Whereas well-defined contra-indications for central pancreatectomy are lacking, not all patients with pre-malignant or low-grade malignant neoplasms in the body or neck of the pancreas are eligible. The most important selection criteria are probably the patient's age and condition and tumor characteristics as size and location. A central pancreatectomy would seem more indicated for a younger patient with a small tumor, good performance status, and no diabetes than an elderly patient already suffering from diabetes.
In addition to this, patient selection is as important as experience with the operative technique. It has to be noted that complication and mortality rates are reduced in centers performing at least 20 robotic pancreatoduodenectomy procedures per year. For this reason, the Miami guidelines advise to only perform this procedure in high volume centers by experienced surgeons18,21.
With regard to the choice of anastomosis, despite the good clinical outcomes of the pancreatico-jejunostomy in our report, the question remains how this anastomosis compares to a pancreatico-gastrostomy. No reliable evidence is available to support the use of one particular anastomosis22.
In conclusion, we have shown that robotic central pancreatectomy with Roux-en-Y pancreaticojejunostomy is a feasible and safe parenchyma-sparing minimally invasive alternative to open or laparoscopic central pancreatectomy or distal pancreatectomy. Unnecessary pancreatic resections with loss of parenchyma and thereby potential loss of long-term pancreatic function could thus be avoided. The general applicability in non-selected patients remains uncertain.
The authors have nothing to disclose.
We would like to acknowledge Melissa Hogg, Herbert Zeh III, Amer Zureikat, and Safi Dokmak for training and advice regarding robotic pancreatic surgery and central pancreatectomy. This clinical research was enabled by HPB-Amsterdam.
SYSTEMS | |||
Arietta Ultrasound | Hitachi | L43K / arietta v70 | Used for intraoperative laparoscopic ultrasonography. |
da Vinci Surgeon Console | IS | SS999 | Used to control the surgical robot. |
da Vinci Vision Cart | IS | VS999 | The vision cart houses advanced vision and energy technologies and provides communications across da Vinci system components. |
da Vinci Xi | IS | K131861 | The surgical robot: ’patient side-cart’ |
INSTRUMENTS | |||
Cobra Liver Retractor Diamond-Flex | CareFusion | 89-6216 | Retracting the liver for optimal exposure of the surgical site. |
da Vinci Xi Endoscope with Camera, 8 mm, 30° | IS | 470027 | The camera of the da Vinci robot. |
ENDOEYE Rigid Video Laparoscope, 10 mm, 30° | Olympus | WA50042A | To see within the intra-abdominal cavity. |
ENDOWRIST Fenestrated Bipolar Forceps | IS | 470205 | Used for dissection and coagulation. |
ENDOWRIST HOT SHEARS | IS | 470179 | Used for cutting and coagulation. |
ENDOWRIST Mega SutureCut Needle Driver | IS | 470309 | Used as a needle driver. |
ENDOWRIST Permanent Cautery Hook | IS | 470183 | Used for coagulation. |
ENDOWRIST PROGrasp Forceps | IS | 470093 | Used for dissecton. |
LigaSure Maryland Jaw | Medtronic | LF1937 | Used for vessel sealing and dividing. |
SUTURES/STENTS | |||
Vicryl 4-0 8cm x2 | |||
V-loc barbed 3-0 15 cm x1 | |||
Silk 2-0 20cm x3 | |||
PDS 5-0 8cm 8-10x | |||
Standing suture Vicryl 50 cm x1 | |||
Internal pancreatic duct stent 4.8 French |